Kymera Therapeutics (KYMR) EBT Margin (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly EBT Margin of 1439.7% for Q1 2026, down 55098.0% year-over-year from N/an in Q1 2025, and up 57.79% quarter-over-quarter from 3411.01% in Q4 2025.
Kymera Therapeutics (KYMR) EBT Margin (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported EBT Margin for 8 consecutive years, with 1439.7% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin fell 55098.0% year-over-year to 1439.7%; the TTM figure through Mar 2026 stood at 2241.92% (down 121204.0% YoY), while the FY2025 annual figure was 1912.45%, down 85483.0% from the prior year.
- EBT Margin grew to 1439.7% in Q1 2026 per KYMR's latest filing, from 3411.01% in the prior quarter.
- Across five years, EBT Margin topped out at 143.96% in Q4 2023 and bottomed at 12394.21% in Q3 2025.
- Historically, EBT Margin has averaged 2311.24% across 5 years, with a median of 1187.89% in 2023.
- On a YoY basis, EBT Margin climbed as much as 94891 bps in 2025 and fell as far as 647855 bps in 2025.
- Kymera Therapeutics' EBT Margin stood at 239.74% in 2022, then surged by 40 bps to 143.96% in 2023, then plunged by 659 bps to 1092.39% in 2024, then plunged by 212 bps to 3411.01% in 2025, then soared by 58 bps to 1439.7% in 2026.
- Business Quant data shows KYMR's EBT Margin at 1439.7% in Q1 2026, 3411.01% in Q4 2025, and 12394.21% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | -1,122.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,122.18% |
| Mar 31, 2026 | -1,439.70% |
| Dec 31, 2025 | -3,411.01% |
| Sep 30, 2025 | -12,394.21% |
| Jun 30, 2025 | -1,906.61% |
| Mar 31, 2025 | -888.72% |
| Dec 31, 2024 | -1,092.39% |
| Sep 30, 2024 | -5,915.66% |
| Jun 30, 2024 | -420.89% |
| Mar 31, 2024 | -1,837.63% |
| Dec 31, 2023 | -143.96% |
| Sep 30, 2023 | -3,921.15% |
| Jun 30, 2023 | -1,010.91% |
| Mar 31, 2023 | -1,187.89% |
| Dec 31, 2022 | -239.74% |
| Sep 30, 2022 | -988.35% |
| Jun 30, 2022 | -741.27% |
| Mar 31, 2022 | -1,751.05% |
| Dec 31, 2021 | -222.77% |
| Sep 30, 2021 | -1,329.11% |